Shachar S, Ziv O, Avkin S, et al. Two-polymerase mechanisms dictate error-free and error-pro ne translesion DNA synthesis in mammals[J]. EMBO J, 2009, 28(4):383.
[2]
Roos W P, Tsaalbi-Shtylik A, Tsaryk R, et al. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs[J]. Mol Pharmacol, 2009, 76(4):927.
[3]
Wang H, Zhang S Y, Wang S, et al. REV3L confers chemoresistance to cisplatin in human gliomas: the potential of its RNAi for synergistic therapy[J]. Neuro Oncol, 2009, 11(6):790.
[4]
Albertella M R, Green C M, Lehmann A R, et al. A role for polymerase eta in the cellular tolerance to cisplatin-induced damage[J].Cancer Res, 2005, 65(21):9799.
[5]
Meijer C, Timmer A, De Vries E G, et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumours[J]. Int J Cancer, 2000, 85(6):777.
[6]
Michaud W A, Nichols A C, Mroz E A, et al. Bcl-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma[J]. Clin Cancer Res, 2009, 15(5):1645.
[7]
Jain H V, Meyer-Hermann M. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas[J].Cancer Res, 2011, 71(3):705.
[8]
Liu J L, Wang Y, Jiang J, et a1. Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA[J].Chin Med J(Ensl), 2010, 123(20):2901.
[9]
Ma J J, Chen B L, Xin X Y, et a1. XIAP gene down regulation by Small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma[J]. Eur J Obstet Gynecol Reprod Biol, 2009, 146(2):222.
[10]
Janson V, Johansson A, Grankvist K. Resistance to caspase-8 and -9 fragments in a malignant pleural mesothelioma cell line with acquired cisplatin-resistance[J]. Cell Death Dis1, 2010, 1: e78.
Galanski M. Recent developments in the field of anticancer platinum complexes[J]. Recent Pat Anticancer Drug Discov, 2006, 1(2): 285.
[14]
Armstrong D K, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J].N Engl J Med, 2006, 354(1): 34.
[15]
Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs[J]. Drug Resist Updat, 2002, 5(3/4):147.
[16]
Timerbaev A R, Hartinger C G, Aleksenko S S, et al. Interactions of antitumor metallodrugs with serum proteins:advances in characterization using modern analytical methodology[J]. Chem Rev, 2006, 106(6):2224.
[17]
Ishida S, Lee J, Thiele D J, et al. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals[J]. Proc Natl Acad Sci USA, 2002, 99(22):14298.
[18]
More S S, Akil O, Ianculescu A G, et al. Role of the copper transporter, CTR1, in platinum-induced ototoxicity[J]. J Neurosci, 2012, 30(28):9500.
[19]
Blair B G, Larson C A, Safaei R, et al. Copper transporter 2 regulates the cellular accumulation and cytotoxocity of cisplatin and carboplation[J]. Clin Cancer Res, 2009, 15(13):4312.
[20]
Safaei R, Katano K, Samimi G, et al. Cross-resistance to cisplatin in cells with acquired resistance to copper[J]. Cancer Chemother Pharmacol, 2004, 53(3):239.
[21]
Nakayama K, Kanzaki A, Terada K, et al. Prognostic value of the Cu-transporting ATPase in ovarian carcinoma patients receiving cisplatin-based chemotherapy[J].Clin Cancer Res, 2004, 10(8):2804.
[22]
Aida T, Takebayashi Y, Shimizu T, et al.Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a prognostic factor in human endometrial carcinoma[J]. Gynecol Oncol, 2005, 97(1):41.
[23]
Yamasaki M, Makino T, Masuzawa T, et al. Role of multidrug resistance protein 2(MRP2) in chemoresistance and clinical outcome in oesophageal squamous cell carcinoma[J]. Br J Cancer, 2011, 104(4):707.
[24]
Wang W, Ke S, Chen G, et al. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines[J]. Oncol Rep, 2004, 12(6):1365.
[25]
Lewis A D, Hayes J D, Wolf C R. Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived rom a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects[J]. Carcinogenesis, 1998, 9(7):1283.
[26]
Meijer C, Timmer A, De Vries E G, et al. Role of metallothionein in cisplatin sensitivity of germ-cell tumours[J]. Int J Cancer, 2000, 85(6):777.
[27]
Ahmad A, Robinson A R, Duensing A, et al. ERCC1-XPF endonuclease facilitates DNA double-strand break repair[J]. Mol Cell Biol, 2008, 28(16):5082.
[28]
Olaussen K A, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med, 2006, 355(10):983.
[29]
Zhen W, Link CJ Jr, O\'Connor P M, et al. Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines[J]. Mol Cell Biol, 1992, 12(9):3689.
[30]
Olaussen K A. A new step ahead for the consideration of ERCC1 as a candidate biomarker to select NSCLC patients for the treatment of cetuximab in combination with cisplatin[J].Cancer Biol Ther, 2009, 8(20):1922.
[31]
Bassett E, Vaisman A, Tropea K A, et al. Frameshifts and deletions during in vitro translesion synthesis past Pt-DNA adducts by DNA polymerases beta and eta[J]. DNA Repair(Amst), 2002, 1(12):1003.
[32]
Siddik Z H. Cisplatin:mode of cytotoxic action and molecular basis of resistance[J]. Oncogene, 2003, 22(47):7265.
[33]
Kama N S, Soria J C, Mendiboure J, et al. MutS homologue 2 and the long-term benefit of adjuvant chemotherapy in lung cancer[J]. Clin Cancer Res, 2010, 16(4):1206.
[34]
Feldman D R, Bosl G J, Sheinfeld J, et al. Medical treatment of advanced testicular cancer[J]. JAMA, 2008, 299(6):672.
[35]
Xu G W, Mymryk J S, Cairncross J G. Inactivati on of p53 sensitizes astrocytic glioma cells to BCNU and temozolomide, but not cisplatin[J]. J Neurooncol, 2005, 74(2):141.
[36]
Huerta S, Heinzerling J H, Anguiano-Hernandez Y M, et al. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF[J]. J Surg Res, 2007, 142(1):184.
Zhang Y, Wang C, Wang H, et al. Combination of tetrandrine with cisplatin enhances cytotoxicity through growth suppression and apoptosis in ovarian cancer in vitro and in vivo[J].Cancer Lett, 2011, 304(1):21.
[41]
Ye M X, Zhao Y L, Li Y, et al. Curcumin reverses cis-platin resistance and promotes human lung adenocarcinoma A549/DDP cell apoptosis through HIF-1α and caspase-3 mechanisms[J]. Phytomedicine, 2012, 9(8/9):779.
[42]
Lin Y G, Kunnumakkara A B. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway[J]. Clin Cancer Res, 2007, 13(11):3423.
